Table 2.
Agreement of clinical and ultrasound findings with 68Ga-FAPI-04 uptake
| 68Ga-FAPI-04 uptake | ||||
| Absent | Present | Total | ||
| Physical examination at baseline | Non-tender | 2074 86.4% |
149 6.2% |
2223 92.6% |
| Tender | 141 5.9% |
36 1.5% |
177 7.4% |
|
| Total | 2215 92.3% |
185 7.7% |
2400 100% |
|
| 68Ga-FAPI-04 uptake | ||||
| Absent | Present | Total | ||
| Ultrasound | Changes absent | 235 75.6% |
13 4.2% |
248 79.8% |
| Changes present | 58 18.6% |
5 1.6% |
63 20.2% |
|
| Total | 293 94.2% |
18 5.8% |
311 100% |
|
68Ga-FAPI-04, 68gallium-labelled fibroblast activation protein inhibitor-04.